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Introduction
============

The first quarter of 2020 has been plagued by the emergence of a novel coronavirus disease, COVID-19 or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 was first identified in Wuhan, China, and has since spread globally at an alarming rate, with over 200 countries and territories being infected ^[@ref-1],\ [@ref-2]^. In March 2020, SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO) ^[@ref-3]^, and as of 18 July 2020, there are over 14 million confirmed cases with over 594,000 deaths worldwide. These figures are expected to rise ( <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>) ^[@ref-2]^. With the emergence of SARS-CoV-2, there are currently over 2,400 listed studies on the National Institute of Health database ( <https://clinicaltrials.gov/ct2/results?cond=COVID-19>) aimed at identifying a solution to this pandemic. The development of a much-needed vaccine against SARS-CoV-2 is of utmost importance. To date, there are more than 100 vaccine candidates being developed by industry and academic institutions using a wide range of technologies including live attenuated, viral vectored, DNA/RNA-based, protein-based, and inactivated vaccines ^[@ref-4]--\ [@ref-6]^. At the time of writing, 19 vaccines are recorded as being in clinical trials ( [Table 1](#T1){ref-type="table"}) ^[@ref-4]--\ [@ref-7]^. This article highlights various technologies employed in vaccine development for COVID-19, potential hurdles, and recent advances.

###### Vaccine platforms and their current status.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Technology\                                                            Developer                                                                     Type of vaccine candidate                                                 Current stage in\
  employed                                                                                                                                                                                                                       clinical evaluation
  ---------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------- ---------------------
  **Non-**\                                                              University of Oxford/AstraZeneca                                              ChAdOx1-S                                                                 Phase III
  **replicating**\                                                                                                                                                                                                               
  **viral vector**                                                                                                                                                                                                               

  CanSino Biologics Inc and Beijing Institute of Biotechnology           Adenovirus type 5 vector                                                      Phase II                                                                  

  Shenzhen Geno-Immune Medical Institute                                 Lentivirus modification                                                                                                                                 

  Gamaleya Research Institute                                            Adeno-based                                                                   Phase I                                                                   

  GeoVax/BravoVax                                                        Modified Vaccinia Ankara (MVA)-encoded virus-like particle (VLP)              Pre-clinical                                                              

  Stabilitech Biopharma Ltd                                              Oral Ad5 S                                                                                                                                              

  Janssen Pharmaceutical Companies                                       Ad26 (alone or witd MVA boost)                                                                                                                          

  Altimmune                                                              Adenovirus-based NasoVAX expressing SARS-CoV-2 Spike protein                                                                                            

  Greffex                                                                Ad5 S (GREVAX™ platform)                                                                                                                                

  Vaxart                                                                 Oral vaccine platform                                                                                                                                   

  DZIF -- German Center for Infection Research                           MVA-S encoded                                                                                                                                           

  IDIBAPS-Hospital Clinic, Spain                                         MVA-S                                                                                                                                                   

  Greffex                                                                Ad5 S (GREVAX™ platform)                                                                                                                                

  Centro Nacional de Biotecnología (CNB-CSIC), Spain                     MVA expressing structural proteins                                                                                                                      

  Reitdera/LEUKOCARE/Univercells                                         Replication defective Simian adenovirus (gRAd) encoding SARS-CoV-2 S                                                                                    

  Valo tderapeutics Ltd                                                  Adenovirus-based + HLA-matched peptides                                                                                                                 

  National Center for Genetic Engineering and Biotechnology\             Inactivated flu-based SARS-CoV2 vaccine + adjuvant                                                                                                      
  (BIOTEC)/GPO, Thailand                                                                                                                                                                                                         

  University of Manitoba                                                 Dendritic cell-based vaccine                                                                                                                            

  University of Georgia/University of Iowa                               Parainfluenza virus 5 (PIV5)-based vaccine expressing tde Spike protein                                                                                 

  Bharat Biotech/Thomas Jefferson University                             Recombinant deactivated rabies virus containing S1                                                                                                      

  Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis        Adeno-associated virus vector (AAVCOVID)                                                                                                                

  ImmunityBio, Inc. and NantKwest, Inc.                                  \[E1-, E2b-, E3-\] hAd5-COVID19-Spike/nucleocapsid                                                                                                      

  National Research Centre, Egypt                                        Influenza A H1N1 vector                                                                                                                                 

  **RNA**                                                                Moderna/NIAID                                                                 Lipid nanoparticle (LNP)-encapsulated mRNA                                Phase II

  BioNTech/Fosun Pharma/Pfizer                                           Three LNP-mRNAs                                                               Phase I/II                                                                

  CureVac                                                                mRNA                                                                          Phase I                                                                   

  People\'s Liberation Army (PLA) Academy of Military Sciences/\                                                                                                                                                                 
  Walvax Biotechnology                                                                                                                                                                                                           

  Imperial College London                                                LNP-nCoVsaRNA                                                                                                                                           

  University of Tokyo/Daiichi-Sankyo                                     LNP-encapsulated mRNA                                                         Pre-clinical                                                              

  Fudan University/Shanghai JiaoTong University/RNACure\                 LNP-encapsulated mRNA cocktail encoding VLP/receptor-binding\                                                                                           
  Biopharma                                                              domain (RBD)                                                                                                                                            

  China CDC/Tongji University/Stermina                                   mRNA                                                                                                                                                    

  Arcturus Therapeutics/Duke-NUS Medical School                                                                                                                                                                                  

  FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                                                                                                                                                                                  

  Greenlight Biosciences                                                                                                                                                                                                         

  IDIBAPS-Hospital Clinic, Spain                                                                                                                                                                                                 

  BIOCAD                                                                 Liposome-encapsulated mRNA                                                                                                                              

  Centro Nacional de Biotecnología (CNB-CSIC), Spain                     Replicating defective SARS-CoV-2-derived RNAs                                                                                                           

  Translate Bio/Sanofi Pasteur                                           LNP-mRNA                                                                                                                                                

  CanSino Biologics/Precision NanoSystems                                                                                                                                                                                        

  Chula Vaccine Research Center/University of Pennsylvania                                                                                                                                                                       

  RNAimmune, Inc.                                                        Several mRNA candidates                                                                                                                                 

  eTheRNA                                                                mRNA in an intranasal delivery system                                                                                                                   

  **DNA**                                                                INOVIO Pharmaceuticals                                                        DNA plasmid vaccine with electroporation device                           Phase I/II

  Cadila Healthcare Limited                                              DNA plasmid vaccine                                                           Phase I/II (not yet\                                                      
                                                                                                                                                       recruiting)                                                               

  Genexine Consortium                                                    DNA vaccine (GX-19)                                                           Phase I                                                                   

  Takis Biotech/Applied DNA Sciences/EvviVax                             DNA                                                                           Pre-clinical                                                              

  BioNet-Asia                                                            DNA vaccine                                                                                                                                             

  Entos Pharmaceuticals                                                                                                                                                                                                          

  Mediphage Bioceuticals/University of Waterloo                          msDNA vaccine                                                                                                                                           

  Zydus Cadila                                                           DNA plasmid vaccine                                                                                                                                     

  Karolinska Institute/Cobra Biologics (OPENCORONA Project)              DNA with electroporation                                                                                                                                

  Chula Vaccine Research Center                                                                                                                                                                                                  

  Osaka University/AnGes/Takara Bio                                      DNA plasmid vaccine                                                                                                                                     

  Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet, Inc.              Plasmid DNA, needle-free delivery                                                                                                                       

  Symvivo                                                                bacTRL-Spike                                                                                                                                            

  Scancell/University of Nottingham/ Nottingham Trent University         DNA plasmid vaccine RBD and N                                                                                                                           

  National Research Centre, Egypt                                        DNA plasmid vaccine S, S1, S2, RBD, and N                                                                                                               

  **Inactivated**                                                        Sinovac                                                                       Formaldehyde-inactivated + alum                                           Phase III (not yet\
                                                                                                                                                                                                                                 recruiting)

  Beijing Institute of Biological Products/Sinopharm                     Inactivated                                                                   Phase I/II                                                                

  Wuhan Institute of Biological Products/Sinopharm                                                                                                                                                                               

  Institute of Medical Biology, Chinese Academy of Medical Sciences      Phase I                                                                                                                                                 

  Osaka University/BIKEN/NIBIOHN                                         Unknown                                                                       Pre-clinical                                                              

  Sinovac/Dynavax                                                        Inactivated + CpG 1018                                                                                                                                  

  Valneva/Dynavax                                                                                                                                                                                                                

  National Research Centre, Egypt                                        Inactivated whole virus                                                                                                                                 

  Beijing Minhai Biotechnology Co., Ltd.                                 Inactivated                                                                                                                                             

  Research Institute for Biological Safety Problems, Rep of Kazakhstan                                                                                                                                                           

  **Live**\                                                              Codagenix/Serum Institute of India                                            Deoptimized live attenuated vaccines                                      Pre-clinical
  **attenuated**\                                                                                                                                                                                                                
  **virus**                                                                                                                                                                                                                      

  Indian Immunologicals Limited/Griffith University                      Codon de-optimization of live attenuated vaccine                                                                                                        

  UMC Utrecht/Radboud University                                         Recombinant BCG (rBCG) technology                                                                                                                       

  **Protein**\                                                           Novavax                                                                       Full-length recombinant SARS CoV-2 glycoprotein nanoparticle\             Phase I/II
  **subunit**                                                                                                                                          vaccine adjuvanted with Matrix (M)                                        

  Clover Biopharmaceuticals Inc./GSK/Dynavax                             Native like trimeric subunit Spike protein vaccine                            Phase I                                                                   

  Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology,\     Adjuvanted recombinant protein (RBD-dimer)                                                                                                              
  Chinese Academy of Sciences                                                                                                                                                                                                    

  Vaxine Pty Ltd/Medytox                                                 Recombinant Spike protein with Advax™ adjuvant                                                                                                          

  ExpreS2ion Biotechnologies                                             Drosophila S2 insect cell expression system VLPs                              Pre-clinical                                                              

  Osaka University/BIKEN/National Institutes of Biomedical\              VLP recombinant protein + adjuvant                                                                                                                      
  Innovation, Japan                                                                                                                                                                                                              

  Chulalongkorn University/GPO, Thailand                                 RBD protein fused with Fc of immunoglobulin G + adjuvant                                                                                                

  AdaptVac (PREVENT-nCoV consortium)                                     Capsid-like particle                                                                                                                                    

  Helix Biogen Consult, Ogbomoso, and Trinity Immonoefficient\           Subunit                                                                                                                                                 
  Laboratory, Ogbomoso, Oyo State, Nigeria                                                                                                                                                                                       

  WRAIR/USAMRIID                                                         S protein                                                                                                                                               

  AJ Vaccines                                                                                                                                                                                                                    

  EpiVax/University of Georgia                                                                                                                                                                                                   

  National Institute of Infectious Diseases, Japan                       S protein + adjuvant                                                                                                                                    

  Sanofi Pasteur/GSK                                                     S protein (baculovirus production)                                                                                                                      

  University of Virginia                                                 S subunit intranasal liposomal formulation with GLA/3M052 adjuvants                                                                                     

  ImmunoPrecise/LiteVax BV                                               Spike-based (epitope screening)                                                                                                                         

  Vaxil Bio                                                              Peptide                                                                                                                                                 

  Flow Pharma Inc                                                                                                                                                                                                                

  IMV Inc                                                                Peptide antigens formulated in lipid nanoparticle formulation                                                                                           

  Generex/EpiVax                                                         Ii-Key peptide                                                                                                                                          

  EpiVax                                                                 Protein subunit EPV-CoV-19                                                                                                                              

  National Research Centre, Egypt                                        Protein subunit S, N, M and S1 protein                                                                                                                  

  Heat Biologics/University of Miami                                     gp-96 backbone                                                                                                                                          

  University of Queensland/GSK/Dynavax                                   Molecular clamp stabilized Spike protein                                                                                                                

  Baylor College of Medicine                                             S1 or RBD protein                                                                                                                                       

  iBio/CC-Pharming                                                       Subunit protein, plant produced                                                                                                                         

  VIDO-InterVac, University of Saskatchewan                              Adjuvanted microsphere peptide                                                                                                                          

  LakePharma, Inc.                                                       Nanoparticle vaccine                                                                                                                                    

  Baiya Phytopharm/Chula Vaccine Research Center                         Plant-based subunit\                                                                                                                                    
                                                                         (RBD-Fc + adjuvant)                                                                                                                                     

  Biological E Ltd                                                       Adjuvanted protein subunit (RBD)                                                                                                                        

  University of Saskatchewan                                             Adjuvanted microsphere peptide                                                                                                                          

  University of Pittsburgh                                               Microneedle arrays S1 subunit                                                                                                                           

  Saint-Petersburg Scientific Research Institute of Vaccines and\        Recombinant protein, nanoparticles (based on S-protein and other\                                                                                       
  Serums                                                                 epitopes)                                                                                                                                               

  Innovax/Xiamen University/GSK                                          COVID-19 XWG-03 truncated S (Spike) proteins                                                                                                            

  OncoGen                                                                Synthetic long peptide vaccine candidate for S and M proteins                                                                                           

  MIGAL Galilee Research Institute                                       Oral *Escherichia coli*-based protein expression system of S and N proteins                                                                             

  Lomonosov Moscow State University                                      Structurally modified spherical particles of the tobacco mosaic virus\                                                                                  
                                                                         (TMV)                                                                                                                                                   

  University of Alberta                                                  Spike-based                                                                                                                                             

  AnyGo Technology                                                       Recombinant S1-Fc fusion protein                                                                                                                        

  Yisheng Biopharma                                                      Recombinant protein                                                                                                                                     

  Vabiotech                                                              Recombinant S protein in IC-BEVS                                                                                                                        

  Applied Biotechnology Institute, Inc.                                  Orally delivered, heat-stable subunit                                                                                                                   

  Medigen Vaccine Biologics Corporation/NIAID/Dynavax                    S-2P protein + CpG 1018                                                                                                                                 

  National University of San Martin and CONICET, Argentina               Protein subunit                                                                                                                                         

  MOGAM Institute for Biomedical Research, GC Pharma                                                                                                                                                                             

  Axon Neuroscience SE                                                   Peptides derived from Spike protein                                                                                                                     

  Intravacc/EpiVax                                                       Outer membrane vesicle (OMV) subunit                                                                                                                    

  OMV peptide                                                                                                                                                                                                                    

  Neovii/Tel Aviv University                                             RBD-based                                                                                                                                               

  Kentucky Bioprocessing, Inc                                                                                                                                                                                                    

  Quadram Institute                                                      OMV-based vaccine                                                                                                                                       

  BiOMViS Srl/University of Trento                                                                                                                                                                                               

  FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                          Peptide vaccine                                                                                                                                         

  Subunit vaccine                                                                                                                                                                                                                

  **Virus-like particles**                                               Medicago Inc./Université Laval                                                Plant-derived VLP                                                         Pre-clinical

  Saiba GmbH                                                             VLP based on RBD displayed on VLPs                                                                                                                      

  Navarrabiomed, Oncoimmunology group                                    VLPs, lentivirus and baculovirus vehicles                                                                                                               

  VBI Vaccines Inc.                                                      Enveloped VLP (eVLP)                                                                                                                                    

  Mahidol University/The Government Pharmaceutical Organization\         VLP + adjuvant                                                                                                                                          
  (GPO)/Siriraj Hospital                                                                                                                                                                                                         

  IrsiCaixa AIDS Research Institute/IRTA-CReSA/Barcelona\                S protein integrated in HIV VLPs                                                                                                                        
  Supercomputing Centre/Grifols                                                                                                                                                                                                  

  Imophoron Ltd and Bristol University Max Planck Centre                 ADDomer™ multiepitope display                                                                                                                           

  Doherty Institute                                                      Unknown                                                                                                                                                 

  OSIVAX                                                                 VLP                                                                                                                                                     

  University of Sao Paulo                                                VLPs/whole virus                                                                                                                                        

  ARTES Biotechnology                                                    eVLP                                                                                                                                                    

  **Replicating**\                                                       Shenzhen Geno-Immune Medical Institute                                        Minigenes engineered based on multiple viral genes, using an\             Phase I
  **viral vector**                                                                                                                                     efficient lentiviral vector system (NHP/TYF) to express viral proteins\   
                                                                                                                                                       and immune modulatory genes                                               

  Cadila Healthcare Limited                                              Measles vector                                                                Pre-clinical                                                              

  Institute Pasteur/Themis/University of Pittsburg Center for Vaccine\                                                                                                                                                           
  Research                                                                                                                                                                                                                       

  FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                                                                                                                                                                                  

  DZIF -- German Center for Infection Research/CanVirex AG               Measles virus (S, N targets)                                                                                                                            

  Tonix Pharmaceuticals/Southern Research                                Horsepox vector expressing S protein                                                                                                                    

  University of Hong Kong                                                Influenza vector expressing RBD                                                                                                                         

  IAVI/Merck                                                             Replication-competent vesicular stomatitis virus (VSV) chimeric virus\                                                                                  
                                                                         technology (VSVΔG) delivering the SARS-CoV-2 Spike (S) glycoprotein                                                                                     

  BIOCAD and IEM                                                         Live viral vectored vaccine based on attenuated influenza virus\                                                                                        
                                                                         backbone (intranasal)                                                                                                                                   

  Lancaster University, UK                                               Avian paramyxovirus vector (APMV)                                                                                                                       

  FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo                          Recombinant vaccine based on influenza A virus for the prevention of\                                                                                   
                                                                         COVID-19 (intranasal) VSV vector                                                                                                                        

  University of Western Ontario                                          VSV-S                                                                                                                                                   

  Israel Institute for Biological Research/Weizmann Institute of\                                                                                                                                                                
  Science                                                                                                                                                                                                                        

  Fundação Oswaldo Cruz and Instituto Butantan                           Attenuated influenza expressing an antigenic portion of the Spike\                                                                                      
                                                                         protein                                                                                                                                                 

  Intravacc/Wageningen Bioveterinary Research/Utrecht University         Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)                                                                                                   

  UW--Madison/FluGen/Bharat Biotech                                      M2-deficient single replication (M2SR) influenza vector                                                                                                 

  **Unknown**                                                            Tulane University                                                             Unknown                                                                   Pre-clinical
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The table was adapted from ^[@ref-5],\ [@ref-6],\ [@ref-21]^.

DNA/RNA-based platforms
=======================

DNA- and RNA-based platforms present the greatest potential for speed of production since culturing and fermentation are not required for their synthesis. The potential of this approach is showcased by Moderna, whose vaccine candidate advanced to clinical testing just 2 months after sequence identification ^[@ref-7]^. There are many other advantages associated with DNA-based vaccines. Notably, they are renowned for their safety profile since the vectors employed are non-replicating and encode and express only the target antigen. The vectors therefore are unable to revert to a disease-causing form, which is a risk with viral vectors. Another key advantage with DNA-based vaccination is the absence of vector-specific immunity, which allows these products to be utilized in prime and boost regimens with multiple products intended for the same patient ^[@ref-8]^. RNA-based vaccines are also a promising alternative owing to their potential for low-cost manufacture and good safety profile in animal studies ^[@ref-9]--\ [@ref-11]^. However, both DNA- and RNA-based vaccines have their own set of challenges. Both vaccines could suffer from the drawback of having low immunogenicity, as DNA vaccines could potentially integrate into the human genome, while there are concerns about the stability of RNA vaccines ^[@ref-12]^. As there are currently no approved DNA or RNA vaccines for medical use in humans ^[@ref-12],\ [@ref-13]^, the question about low immunogenicity has not yet been resolved ( [Table 2](#T2){ref-type="table"}). The lack of currently approved DNA or RNA vaccines provides considerable regulatory uncertainty, and their progression through the regulatory process will almost certainly take significantly longer than for more conventional vaccine technologies. Currently, there is one vaccine in phase II clinical trials, three in phase I/II clinical trials, and four in phase I clinical trials for SARS-CoV-2 based on the DNA/RNA platform. Inovio Pharmaceuticals is developing a SARS-CoV-2 vaccine, INO-4800, using a DNA-based platform, with phase I clinical trials being undertaken in conjunction with pre-clinical studies in order to hasten development ^[@ref-14]^. The International Vaccine Institute (IVI) has announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded \$6.9 million of funding to INOVIO to work with IVI and the Korea National Institute of Health (KNIH) for a phase I/II clinical trial of INO-4800 in South Korea. The trial will be conducted in parallel with INOVIO's phase I study, which is currently ongoing with 40 healthy adults receiving the vaccine candidate and will eventually be expanded to older adults ^[@ref-15]^. An RNA vaccine candidate, mRNA-1273, is being developed by Moderna in collaboration with NIAID. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), has agreed to cooperate to hasten the development of mRNA-1273 by pledging up to \$483 million in funding ^[@ref-16]^. Healthy adults aged 18 to 55 were recruited for phase I trials. Two injections of mRNA-1273 were given 28 days apart at a dose of 25 μg, 100 μg, or 250 μg. Dire adverse events were absent, and no trial halting rules were met, although one participant in the 25 μg group withdrew because of an unsolicited adverse event, transient urticaria, which was postulated to be linked to the first vaccination. Live virus neutralization capable of reducing SARS-CoV-2 infectivity by 80% or more was detected at day 43 post-vaccination in all participants. Of the three doses evaluated, the 100 μg dose was optimal based on its capacity to trigger high neutralization responses and Th1-skewed CD4 T cell responses. The reactogenicity profile at 100 μg was better than for the other two doses. The safety, reactogenicity, and immunogenicity of mRNA-1273 are currently being evaluated in phase II trials using two vaccinations given 28 days apart. A total of 600 participants, 300 aged 18--54 and 300 aged 55 and above, have been assigned to three groups: placebo, 50 μg of vaccine, or 100 μg of vaccine at both vaccinations ^[@ref-17]^. A phase III trial of mRNA-1273 is expected to begin in July with an estimated 30,000 participants. With the expected final dose of 100 μg, Moderna is confident to scale up manufacturing to approximately 500 million to 1 billion doses per year ^[@ref-18]^.

###### Pros and cons of different vaccine formulations and examples of licensed vaccines.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine platforms                Pros                                   Cons                                    Examples of licensed vaccines\
                                                                                                                  targeted for humans
  -------------------------------- -------------------------------------- --------------------------------------- ---------------------------------------
  **RNA**                          •   Potential low-cost\                •   May have low immunogenicity\        \-
                                   manufacturing\                         due to instability\                     
                                   •   Ease of manufacturing\             •   May require multiple doses          
                                   •   Good safety profile                                                        

  **DNA**                          •   Potential low-cost\                •   Potential integration to human\     \-
                                   manufacturing\                         genome\                                 
                                   •   Ease of manufacturing\             •   Low immunogenicity                  
                                   •   Good safety profile\                                                       
                                   •   Good stability\                                                            
                                   •   Does not induce anti-vector\                                               
                                   immunity                                                                       

  **Virus vectors**\               •   High-efficiency gene\              •   Low titer production\               •   JYNNEOS (Smallpox/\
  **(replicating/non-**\           transduction\                          •   May induce anti-vector\             Monkeypox)\
  **replicating viral vectors**\   •   High specific delivery of genes\   immunity\                               •   ACAM2000 (Smallpox)\
  **and virus-like particles)**    to target cells\                       •   Generation of replication-\         •   Adenovirus type 4 and type 7\
                                   •   Induction of robust immune\        competent virus, which can\             vaccine, live, oral (febrile acute\
                                   responses\                             induce tumorigenesis                    respiratory)
                                   •   Increased cellular immunity                                                

  **Inactivated**                  •   Good safety profile\               •   Requires booster doses\             •   Poliovax (Polio)\
                                   •   Can be used in\                    •   Low production titer                •   Flucelvax Quadrivalent\
                                   immunocompromised patients                                                     (Influenza)\
                                                                                                                  •   Ixiaro (Japanese Encephalitis)\
                                                                                                                  •   Imovax (Rabies)

  **Live attenuated virus**        •   High potency\                      •   Possible regression to virulence\   •   ERVEBO (Ebola virus)\
                                   •   Triggers long-lasting immunity\    strain\                                 •   MMR II (Measles, Mumps, and\
                                   •   Low-cost manufacturing             •   Limited use in\                     Rubella)\
                                                                          immunocompromised patients              •   BCG vaccine (Tuberculosis)

  **Protein subunit**              •   Can be used in\                    •   Low immunogenicity\                 •   PedvaxHIB\
                                   immunocompromised patients\            •   Conjugation could lead to\          ( *Haemophilus* *influenzae* type b)\
                                   •   Good safety profile                batch-wise variation                    •   Engerix-B (Hepatitis B)\
                                                                                                                  •   Recombivax HB (Hepatitis B)
  -------------------------------------------------------------------------------------------------------------------------------------------------------

This table was adapted from ^[@ref-8]--\ [@ref-11],\ [@ref-20],\ [@ref-22]--\ [@ref-28]^.

Virus vectors
=============

Virus-based vectors are powerful tools for vaccination. Their effectiveness stems from their ability to infect cells, which allows them to be highly efficient, specific, and able to trigger robust immune responses. Despite their advantages, viral vectors have several disadvantages ( [Table 2](#T2){ref-type="table"}). For example, the use of vaccinia virus and adenovirus may lead to immunity against the vector, which will reduce the efficacy of the vaccine. The use of retrovirus and lentivirus, on the other hand, may lead to the risk of tumorigenesis in patients, which results from the integration of viral long terminal repeats into proto-oncogenes ^[@ref-19]^. Additionally, certain viral vectors such as adeno-associated virus may not be cost effective owing to their low titer production ^[@ref-20]^. Ultimately, viral vectors still present themselves as a valid choice for vaccine development against SARS-CoV-2, as illustrated by their successful use in the eradication of smallpox ^[@ref-20]^. Examples of such vaccines currently under development are ChAdOx1-S, Ad5-nCoV, aAPC, and LV-SMENP-DC. The latter two vaccines, developed by Shenzhen Geno-Immune Medical Institute, are currently in phase I (aAPC) and phase II (LV-SMENP-DC) clinical studies. The Ad5-nCoV vaccine pioneered by CanSino Biologics is the first SARS-CoV-2 vaccine to reach phase II clinical trials ^[@ref-5]^. Phase I clinical studies for Ad5-nCoV were conducted between March 16 and March 27. No serious adverse events within 28 days of vaccination were reported in vaccine recipients. Specific antibodies, including neutralizing antibodies, increased significantly at day 14 and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination ^[@ref-29]^. A phase II study is currently underway with 500 participants registered in three different groups: 250 participants will receive the vaccine, 125 participants will receive a lower vaccine dose, and 125 participants will receive placebo. The immune response will be tested at 0, 14, and 28 days and 6 months after vaccination ^[@ref-30]^. ChAdOx1-S, developed by the University of Oxford in partnership with AstraZeneca, is the first vaccine candidate to reach phase III clinical trials ^[@ref-1],\ [@ref-5]^. A study has reported that a single dose of the vaccine is able to elicit a strong immune response in rhesus macaques ^[@ref-31]^. Additionally, a trial study conducted in pigs demonstrated that ChAdOx is able to elicit a greater antibody response when given a booster shot, suggesting that a two-dose approach may give better protection in humans against SARS-CoV-2 ^[@ref-32]^. However, it should be noted that nose swabs and oropharynx and mediastinal lymph node testing revealed viral gRNA in both vaccinated and control animal groups at 3 and 5 days post-inoculation. Interestingly, viral genome was detected in cervical lymph node in the vaccinated group but not in the control group. Detection of virus in these tissues indicates the vaccine does not provide complete protection against SARS-CoV-2 infection. Viral RNA (gRNA and sgRNA) load in lung tissue was also shown to vary dramatically between individual animals but was determined to be significantly lower in the vaccinated group than in the control group. Another troubling result to note from this study is that despite observing neutralizing antibodies in vaccinated animals, the titers reported were extremely low ^[@ref-31]^. Generally, neutralizing antibodies elicited by effective vaccines can be diluted more than a thousand-fold and still maintain their effectiveness ^[@ref-33]^. However, the results reported by Oxford show that the serum could be diluted only 4- to 40-fold before losing its neutralizing activity ^[@ref-31],\ [@ref-33]^. ChAdOx1-S was well tolerated in humans, with a trial of over 320 vaccinated individuals showing no strong adverse effects ^[@ref-34]^. The phase III clinical trials of this vaccine will involve 8,000 individuals in the United Kingdom, 5,000 individuals in Brazil, and 2,000 individuals in South Africa ^[@ref-35]^. AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of ChAdOx1-S starting by the end of 2020 at no profit. The total manufacturing capacity of this vaccine currently stands at 2 billion doses ^[@ref-34]^.

Inactivated vaccines
====================

Inactivated vaccines have been successfully employed over the past 70 years and are widely used today ^[@ref-36]^. Inactivated vaccines are produced using bacteria or viruses by deactivating them with heat, chemicals, or radiation. These processes terminate the pathogen's ability to replicate, leading to them being more stable and having higher safety profiles. These attributes allow for their use in immunocompromised individuals ^[@ref-37]^. However, the characteristics that contribute to their strengths are also weaknesses. As the pathogens are inactivated, these vaccines generally stimulate a much weaker immune response than live vaccines and require several doses for effective immunity to be established. The immune response to an inactivated vaccine is also typically humoral. Antibody titers against the targeted antigen will diminish with time, leading to the need for booster shots ^[@ref-22],\ [@ref-36]^ ( [Table 2](#T2){ref-type="table"}). Regardless, inactivated vaccines are effective agents that have prevented countless deaths due to various infections in humans, notably against wild poliovirus 2, which has not been detected since 1999 and was declared eradicated in September 2015 by WHO ^[@ref-38]^. There are currently nine inactivated vaccine candidates for SARS-CoV-2 listed by WHO. Of these, one vaccine candidate---PiCoVacc, developed by Sinovac---is listed as ready to commence phase III clinical trials and is in the midst of preparing to recruit participants. It is very promising to note that Sinovac Biotech has demonstrated protection by PiCoVacc against SARS-CoV-2 in monkeys. Monkeys were immunized three times with two different doses (3 or 6 μg per dose) of PiCoVacc at day 0, 7, and 14 before virus challenge at week 3. It was demonstrated that monkeys vaccinated with PiCoVacc produced anti-SARS-CoV-2 neutralizing antibody titers similar to those of recovered patients. This study also indicated that PiCoVacc is safe, as there was no infection enhancement or immunopathological exacerbation observed in vaccinated monkeys. PiCoVacc is currently in phase I human clinical trials as stated above. The company plans to initiate phase II and III clinical trials with PiCoVacc by the end of this year ^[@ref-39]^. There are two other inactivated vaccine candidates being developed by the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, respectively, both of which are currently in phase I/II clinical trials. Both institutes are collaborating with Sinopharm for the development of these vaccines.

Live attenuated virus
=====================

Another promising approach in vaccine design is the use of live attenuated virus (LAV), developed by codon deoptimization. This technology has proven itself to be cost effective for large-scale manufacturing and has a smooth regulatory approval pathway, as it has demonstrated high efficacy and potency in both *in vitro* and *in vivo* experiments against different respiratory viruses in mice, human cells, and non-human primates, providing lasting immunity with just a single dose ^[@ref-23]--\ [@ref-25]^. LAV have a simple production process using well-established Vero cells, which are currently the most widely accepted cell line by regulatory authorities for vaccine development, since they have been in use for vaccine manufacturing for nearly 40 years. LAVs are also proven to grow and infect microcarrier beads in large-scale fermenters up to 6,000 L and in serum free media with zero loss in production output ^[@ref-40]^. Existing manufacturing infrastructure can be easily utilized because of its cost effectiveness for large-scale manufacturing ^[@ref-41]^. LAV has certain drawbacks, notably the existing possibility of reversion to virulence, which has strong safety implications, especially in immunocompromised patients ^[@ref-26]^ ( [Table 2](#T2){ref-type="table"}). Nonetheless, codon deoptimization technology in vaccine design has promise against SARS-CoV-2. It is a tried and tested new engineering technology, and designs such as introducing point mutations have proved that the drawbacks can be overcome with relative ease ^[@ref-42]^. One example of its recent use is in a vaccine against Ebola virus, where an estimated efficacy of 97.5% was recorded from a preliminary analysis of 90,000 individuals who were exposed for 10 days or more to Ebola virus after vaccination ^[@ref-43]^. Codon deoptimization vaccine candidates have virtually no risk of reversion to virulence because of the large number of substitutions that are made in the coding sequence. This is a crucial safety feature of vaccines developed using codon deoptimization. Vaccines developed against SARS-CoV-2 using LAV technology are all currently in pre-clinical development. For example, Indian Immunologicals Limited is currently working together with Griffith University to develop a vaccine using codon deoptimization as a strategy against SARS-CoV-2. The vaccine candidate is expected to provide a long-lasting immunity against SARS-CoV-2 following a single vaccination and is also expected to provide cross-protection against other coronaviruses such as MERS and SARS-CoV-1 ^[@ref-44]^.

Protein subunit
===============

Protein subunit vaccines are a popular choice for the design of a SARS-CoV-2 vaccine owing to their strong safety profile, which is particularly advantageous for immunocompromised patients. They are less likely to cause complications in vaccinated individuals, as the antigenic components employed in protein subunit vaccines are purified and do not involve the use of infectious viruses ^[@ref-45]^. However, as with other vaccine platforms, protein subunit vaccines come with their own set of challenges, with the most prominent one being their lack of efficacy. A subunit vaccine presents an antigen to the immune system without the involvement of viral particles using a specific, isolated protein of the pathogen. In the likely scenario where the isolated proteins are denatured, they will become associated with other antibodies different from what was initially targeted, leading to the lack of efficacy ^[@ref-46]^ ( [Table 2](#T2){ref-type="table"}). Nonetheless, novel designs and delivery can overcome this limitation and demonstrate enhanced efficacy, e.g. against Zika virus in animal studies and against malaria in *in vivo* studies ^[@ref-47],\ [@ref-48]^. The success of protein subunit vaccines is highlighted by the hepatitis B vaccine, and we have now controlled these diseases to the point of virtual elimination ^[@ref-49],\ [@ref-50]^. Currently, there are many vaccines under pre-clinical studies using this platform. For example, Danish company Expression Biotechnologies has announced that it was awarded an EU horizon 2020 grant amounting to €2.7 million for the development of a SARS-CoV-2 vaccine candidate. The company aims to conduct phase I/IIa clinical trials within 12 months after preliminary studies ^[@ref-51]^. One other notable example of a vaccine candidate designed on the basis of this platform is developed by Novavax, which is currently in phase I/II clinical trials. There are three other protein subunit vaccine candidates currently in phase I clinical trials ^[@ref-5]^.

Outlook
=======

SARS-CoV-2 has given rise to an unprecedented economic, health, and societal challenge globally. The key to tackle this pandemic is the development of safe and effective vaccines. Monumental energy has been poured into vaccine R&D; however, there are many challenges that need to be overcome before a successful marketable vaccine becomes available. Over 100 vaccine candidates are in pre-clinical trials, with 19 in clinical trials and many others in early development ^[@ref-5],\ [@ref-6]^. Vaccine developers are turning a blind eye to industrial benchmarks for traditional vaccine development, as speed is considered a major priority in developing a successful vaccine against SARS-CoV-2. For example, clinical trials are being conducted simultaneously instead of sequentially using adaptive designs that are optimized for speed. Researchers, manufacturers, funders, and governing parties are targeting vaccines to be available by 2021, impelling proposals to move forward with reduced numbers of study participants and cut short safety follow-up in clinical studies. A successful COVID-19 vaccine will be administered on a global scale; thus, its safety profile must be solid. Therefore, approaches for generating a COVID-19 vaccine must not compromise safety aspects and will require careful evaluation of effectiveness and safety at each step to avoid major setbacks. There are also unresolved obstacles in ensuring global access to a developed COVID-19 vaccine. For example, during the early days of the HIV and H1N1 outbreaks, even after the successful development of a vaccine, it was difficult to achieve global distribution. Similarly, for COVID-19, a vaccine approved for marketing does not necessarily lead to easy accessibility. Manufacturing capability must be enhanced so that the production of vaccine doses can be magnified while ensuring vaccine affordability for the global community. Coordinated efforts among vaccine developers, funders, and manufacturers are essential to ensure that successful vaccine candidates can be manufactured in adequate numbers and distributed evenly across the globe.

Another important issue is whether COVID-19 vaccines will sensitize humans to a phenomenon known as antibody-dependent enhancement (ADE). Although antibodies are generally protective, rare cases have been documented in which pathogen-specific antibodies enhance disease---a phenomenon known as ADE. ADE is most prominently associated with dengue virus ^[@ref-52]^. ADE has also been observed for both MERS and SARS-CoV-1 despite evidence pointing towards the fact that coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE exemplified by the dengue viruses. Therefore, ADE warrants full consideration in the safety profiling of potential vaccine candidates against SARS-CoV-2 to avoid this phenomenon being observed, as SARS-CoV-2 shares a high sequence identity with SARS-CoV-1 ^[@ref-53],\ [@ref-54]^.

Safety aspects of the COVID-19 vaccines under development are of the utmost importance. Thorough clinical trials need to be carried out prior to marketing of the vaccine. Recent reports in India on the possibility of launching a vaccine in record time without allowing sufficient time for clinical trials are disturbing. Although COVID-19 vaccine development is of the utmost global importance, it is crucial that we do not cut corners and that vaccines are approved only after having passed through rigorous clinical trials.

Concluding remarks
==================

There are an extraordinary number of COVID-19 vaccines currently under development around the world. Highly optimistic timeframes of 12--18 months to get to the distribution of approved vaccines are being touted. Vaccines typically take many years or even decades to develop, e.g. the smallpox vaccine took 25 years to develop for human use, the HPV vaccine 15 years, the rotavirus vaccine 15 years, and the influenza vaccine 28 years. The COVID-19 vaccine initiatives aspire to have vaccines ready for distribution by 2021. This is a truly remarkable and unprecedented timeframe for vaccine development. The majority of vaccines won't progress beyond pre-clinical or early clinical testing, but, of course, we need only one effective COVID-19 vaccine to halt this pandemic. Fewer than 10% of drugs or vaccines that enter clinical trials ever progress to become available for human use. For example, 30% fail at phase I trials. Of those that progress to phase II, 69% fail and then a further 42% fail at phase III. Of those products that successfully pass through phase III trials, a further 15% do not gain regulatory approval. Because of the drastically shorter time being allotted for the pre-clinical development of COVID-19 vaccine candidates, it is conceivable that a higher proportion of these candidates may fail during clinical testing. In addition to vaccine development, a number of resource-intensive activities will need to be undertaken in parallel, particularly the construction of manufacturing facilities capable of producing at a global scale. We are hopeful the unmatched resources being directed into the international vaccine R&D effort will lead to a successful vaccine capable of stopping this new pandemic.
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